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Pediatric Gastroenterology and Liver Unit, Cliniques St Luc, Université Catholique de Louvain, Brussels, BelgiumIntroductionHepatitis B virus (HBV) infection is still one of the most impor-
tant causes of liver disease, with 2 billion people infected world-
wide and more than 600,000 deaths each year, caused in 94% of
cases by chronic infection-related cirrhosis and hepatocellular
carcinoma (HCC) [1–3]. The World Health Organization (WHO)
estimates more than 360 million persons being chronic carriers
worldwide (6% of the world population). The incidence of HBV
infection has been declining over the last two decades thanks
to the introduction of universal immunization programs and
the implementation of blood-donor screening. Nevertheless, a
signiﬁcant number of adults and children are still infected each
year, the latter often developing chronic infection and requiring
an appropriate follow-up. In spite of a rather benign course of
chronic disease during childhood and adolescence, HBV chronic
carriers have a lifetime risk of developing HCC up to 25%, and
an incidence of cirrhosis of 2–3% per year [4]. Safe and partially
effective antiviral therapies are available, but few are licensed
for use in children, and an accurate selection of subjects to treat
and of the right timing for treatment is needed to optimize
efﬁcacy and reduce viral resistance.
 2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Epidemiology
HBV is transmitted by percutaneous and mucous membrane
exposure to infectious blood, semen, vaginal secretions and saliva
[5]. The extreme resilience of HBV, allowing its survival for more
than a week on dry surfaces, explains the increased risk of hori-
zontal intrafamilial transmission and the need of carriers coun-
seling and household members vaccination [6–9]. Nonetheless,
after 20 years from the introduction of immunization programs,Journal of Hepatology 20
Keywords: Chronic hepatitis B; Children; Epidemiology; Natural history; Vacci-
nation; Prevention; Treatment.
Received 29 October 2011; received in revised form 16 March 2012; accepted 20
March 2012
⇑ Corresponding author. Address: Department of Paediatrics, Université Catho-
lique de Louvain, 10, Av. Hippocrate, 1200 Brussels, Belgium. Tel.: +32 2 764
1386/87.
E-mail address: etienne.sokal@uclouvain.be (E.M. Sokal).
Abbreviations: HBV, hepatitis B virus; HCC, hepatocarcinoma; HBIG, hepatitis B
immunoglobulins; CHB, chronic hepatitis B; ALT, alanine aminotransferases; cc-
cDNA, covalently closed circular DNA; WHO, World Health Organization; ULN,
upper limit of normal; IFN, interferon; FDA, Food and Drug Administration; VR,
virologic response; PegIFN, pegylated interferon.most infants and children are protected against HBV [10], and
chronic carriers should not be isolated in schools or prevented
from practicing sports. Transmission occurs rarely in childcare
settings [7], but the risk is higher in detention centers, where
adolescents are less likely to be immunized and have high-risk
behaviors [11,12].
In highly endemic areas, infection occurs mainly in infancy
and early childhood, with mother-to-child transmission account-
ing for more than half of chronic infections. After exposure, the
risk of developing CHB is indeed higher for newborns (90%) than
for infants and children <5 years of age (25–30%) or adolescents
and adults (<5%) [13,14]. To further reduce mother-to-child
transmission, WHO recommends the administration of both the
vaccine and hepatitis B immunoglobulins (HBIG) to newborns
of HBsAg-positive mothers within 24 h from birth (90–98% pro-
tection rate) [7,15–17]. HBIG administration to newborns of
HBeAg-negative mothers does not change the overall protection
rate but decreases the risk of fulminant hepatitis (higher in this
group), proving to be cost-effective [16,18–20].
Newborns of highly viremic HBeAg-positive mothers are at
increased risk of HBV infection despite proper immunization
(breakthrough infection), compared to babies born to HBeAg-
negative mothers (16.8% vs. 1.6%), and are at increased risk for
chronicity [16,21]. Breakthrough infection is more likely to occur
in newborns of mothers with genotype C, who have higher viral
loads. Vaccination programs are therefore changing the HBV
genotype distribution [22]. Intrauterine infection, hyporespon-
siveness to vaccine, and vaccine escape mutants could play a role
as well [16,21,23,24]. The risk of mother-to-child transmission
also depends on maternal serum HBsAg titer and mode of deliv-
ery (10.5% for elective cesarean section vs. 28% for vaginal deliv-
ery) [21,25,26]. Vertical transmission can be further reduced by
treating highly viremic mothers during the last trimester of preg-
nancy with either lamivudine, telbivudine, or tenofovir (1–2% risk
reduction for lamivudine and 8% for telbivudine) [27–30].
HBsAg and HBV DNA can be detected in breast milk of chronic
carriers, but no increased risk of transmission to a breastfed
infant has been shown and breastfeeding is currently recom-
mended after proper infant immunization [31–33].
WHO has recommended universal HBV vaccination since
1991, with the ﬁrst dose to be administered within 24 h from
birth, followed by at least two doses at 1 and 6 months of life
[15,34–36]. By the end of 2010, 179 of the 193 WHO member
states had implemented a nationwide childhood HBV immuniza-
tion program and global HBV vaccine coverage was estimated at
75% [37]. In countries where such programs have been imple-12 vol. 57 j 885–896
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Reviewmented, prevalence of HBV infection decreased dramatically [38–
40]. Many countries with high HBsAg seroprevalence (P8%)
before vaccination programs (like China and Taiwan) are now
considered at intermediate (2–7%) or low prevalence (<2%)
[38,41–43]. In Taiwan, prevalence of HBsAg in children younger
than 15 years of age decreased from 9.8% to 0.5% after 20 years
of vaccination [42]. In China, HBsAg prevalence in children aged
1–14 years decreased by 83% (from 8% in 1992 to 1.36% in
2006) [44]. In a recent study, 4.6% of the total population of the
Unites States has been exposed to HBV (past or chronic infection),
with up to a 50-fold variation as age, ethnicity and country of
birth vary. HBsAg seroprevalence in children and adolescents
aged 6–12 years and 13–17 years is 0.03% and 0.02%, respec-
tively. Prevalence of both exposure and chronic carrier state is
higher among people coming from high or intermediate preva-
lence countries, and among those with lower family income or
with high-risk behavior [45].
Although, among children born in Western Europe and North
America, prevalence of HBV infection is low, pediatricians and886 Journal of Hepatology 201hepatologists are confronted with an increasing number of chil-
dren adopted from higher prevalence countries (Table 1).
Between 2% and 5% of all internationally adopted children, all
coming from P2% prevalence areas, are still infected with HBV
[46,47]. CDC and American Academy of Pediatrics recommend
screening all children adopted from these countries for HBV
(HBsAg, HBsAb, HBcAb), at arrival and after 6 months, in order
to provide vaccination to those without protective antibody lev-
els (anti-HBs P10 mIU/ml) [15,48] or diagnose a previously
unknown infection and proceed to immunization of household
contacts [6,34,49].
Ten genotypes (A–J) and several subtypes have been described
for HBV, with a distinctive geographic distribution. Although in
most of Europe and North America, genotype A is predominant,
many of the children coming from high or intermediate endemic-
ity countries are infected with genotype B, C, D, or F (Table 1), are
at increased risk of complications and may have a worse response
to therapy [50–52].Natural history
Chronic HBV infection is deﬁned as a positive HBsAg for 6 months
or longer. Chronic hepatitis B (CHB) in childhood is a mild dis-
ease, and infected children are mostly asymptomatic, have nor-
mal growth and a normal physical examination [53]. Most
perinatally infected subjects present a positive HBeAg and high
serum levels of HBV DNA, with normal or minimally elevated
serum alanine aminotransferases (ALT). A transplacental transfer
of maternal HBeAg has been proved both in mice and in humans,
and could elicit HBe/HBcAg-speciﬁc Th cell tolerance in utero
[40,54–56]. Such an induced tolerance could explain the higher
chronicity rate in babies born to HBeAg-positive mothers and
the different rate of chronicity between neonatal and adult infec-
tion. The synthesis of large amounts of HBeAg by the wild type
virus could be necessary to maintain the tolerance [57]. This
immunotolerant phase is characterized by high viral replication
and little liver damage, although in Italian children, after 7 years
of disease, 7–10% of subjects showed severe hepatitis at liver
biopsy and 1.7–4.5% had cirrhosis [53,58]. It lasts 10–30 years
when infection is acquired perinatally, whereas it is of minimal
duration in subjects infected later in life.
Viral mutants not capable of secreting HBeAg are then slowly
selected (pre-core mutants are detected in 89% of HBeAg-positive
patients) [59]. Selection seems to be secondary to an advantage of
such mutants over wild type HBV, as hepatocytes infected by the
latter are more susceptible to cytotoxic T lymphocyte-mediated
clearance [60]. Pre-core mutants selection leads to a lower secre-
tion of HBeAg. When the decreased amount of secreted tolerogen
is no more sufﬁcient to maintain immunotolerance, the immune
system starts attacking infected hepatocytes [56,57]. ALT levels
rise, reﬂecting the bioptic ﬁnding of necroinﬂammation of liver
parenchyma, and HBV DNA levels ﬂuctuate. This phase of active
hepatitis leads to seroconversion to anti-HBe antibodies in 60–
95% of patients on long-term follow-up [58,61]. ALT levels signif-
icantly increase before HBeAg clearance and may remain elevated
for 6 months after seroconversion [53,62–64]. Up to 20% of
spontaneous seroconverters may have ALT ﬂare-ups in the years
following seroconversion, which seems to be more likely in
subjects carrying a pre-core mutant [63]. Spontaneous serocon-
version occurs earlier and more frequently in subjects who have2 vol. 57 j 885–896
Table 1. Estimated HBsAg seroprevalence and HBV genotype in countries of origin of internationally adopted children. (See below-mentioned references for further
information.)
Country [Ref.] HBsAg prevalence 
%
Predominant 
genotypes
Adopted children per year
Total <16 yr United Statesa Italyb Francec Canadad
China [41] 7.2 1.8 B, C 3401 116 100 230
Russian Federation [149] 1.4-8 - D 1079 707 301 66
Ethiopia [150] 4.7 - A 2511 274 352 159
Haiti [151,152] 5 - A 133 0 992 94
Korea [153,154] 5.9 0.9 C 865 4 6 87
Colombia [155] 5.7 3.1 F 235 592 369 25
Vietnam [156] 10 7.5 B, C 9 251 469 29
Ukraine [157] 1-2 - D 450 426 59 35
Brazil [158,159] 1 0.8 A, D, F 26 318 13 1
Taiwan [16,42] 1.1* 0.5 B, C 282 3 3 6
India [160] 2-8 - A, D 241 124 21 36
Philippines [152] 10 - B, C 216 30 14 96
Poland [149,157] 1-2 - A 50 193 26 0
Nigeria [161-163] 4-12 12.4 E 189 5 23 6
Kazakhstan [164] 3.8 - D 181 28 46 45
Bulgaria [149] 2-7 - D 40 128 8 2
Ghana [165] 11.4 - A 117 0 2 9
Belarus [166] 4.8 - D 0 99 0 1
Cambodia [167] 8 2-14 B, C 0 87 2 1
Peru [149] 0.8-5.2 - F 35 83 1 3
Hungary [149] <1 - A, D 5 78 5 0
Others 993 584 692 261
Total 11,058 4130 3504 1192
⁄Prevalence obtained from a study on 18-year old freshmen.
aData refer to year 2010 (Bureau of Consular Affairs, US Department of State. US Intercountry Adoption [Internet]. adoption.state.gov 2011; [cited 10.01.12] Available from:
http://adoption.state.gov/about_us/statistics.php). HBsAg seroprevalence in the United States is 0.27% (0.03% in 6–12 years old) [45].
bData refer to year 2010 (Commission for intercountry adoptions. Data and perspectives in intercountry adoptions in Italy. Report on ﬁles from January 1 to December 31,
2010. Commission for intercountry adoptions; 2011. Available from: http://commissioneadozioni.it/it/per-una-famiglia-adottiva/rapporto-statistico.aspx). HBsAg sero-
prevalence in Italy is 0.9% [168].
cData refer to year 2010 (Agence française de l’adoption. Statistiques de l’adoption international 2010. [Internet]. France Diplomatie 2011; [cited 10.01.12] Available from:
http://www.diplomatie.gouv.fr). HBsAg seroprevalence in France is 0.65% [169].
dData refer to year 2008 (HCCH Hague Conference Statistics. Canada: annual adoption statistics 2005–2009. [Internet]. HCCH 2012; [cited 10.01.12] Available from: http://
www.hcch.net). HBsAg seroprevalence in Canada is 0.3–0.6% (0.4% for preadolescents) [170].
JOURNAL OF HEPATOLOGYacquired HBV horizontally than in those infected perinatally
(14–16% vs. 4–5% per year) [53,58,62,65]. It usually occurs after
puberty, with about 90% of children <15 years of age still HBeAg
positive [65]. It was shown that boys with earlier-onset puberty
seroconverted at younger age (13 vs. 22 years), suggesting that
androgens play a role in this process [64]. Environmental factors,
such as nutritional status, have been suggested to inﬂuence
immune response to HBV, accelerating seroconversion in children
after adoption from developing countries [62]. Genotype C and
maternal HBeAg-positive status were also associated with
delayed spontaneous seroconversion [24,61,62,66–68].
HBsAg-positive, HBeAg-negative, and anti-HBe-positive
patients are considered inactive carriers, express absent or low
viral replication, with low or undetectable HBV DNA, and have
inactive liver histology, with normal ALT levels. Inactive carriers
with no signs of cirrhosis at seroconversion did not show pro-
gression to cirrhosis over 24–29 year follow-up [53,58].Journal of Hepatology 201On the contrary, 1–5% of HBeAg-positive children developed
cirrhosis [53,58,69]. Between 2% and 5% of children with CHB
developed HCC during childhood [24,58,70]. Incidence of HCC
in high prevalence areas was signiﬁcantly reduced after the
implementation of immunization programs [71]. Children devel-
oping HCC are more likely to be males (70%), with cirrhosis (80%)
and undergoing early seroconversion, suggesting that necroin-
ﬂammation during seroconversion to anti-HBe may be severe
and lead to cirrhosis and HCC [24,58,70]. Long-term risk of both
HCC and cirrhosis is directly correlated to viral replication and
serum HBV DNA levels [72,73]. The role of viral genotype on
the risk of developing HCC is still to be deﬁned: in children,
80% of HCCs are present in cirrhotic genotype B patients, whereas
young adults with HCC are mostly non-cirrhotic [24,66]. In
adults, genotypes C and F increase the risk for HCC [66,74–76].
Furthermore, such a risk is higher in persons with a family history
of HCC, and a new susceptibility locus has been recently2 vol. 57 j 885–896 887
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Fig. 1. Who and when to treat: algorithm for treatment of children and adolescents with chronic hepatitis B.
Reviewdescribed in 1p36.22 [77,78]. Seroconversion to anti-HBe reduces
the overall risk of developing HCC later in life, but an annual
incidence of 0.2% has been described in HBeAg-negative adults
(1.6% of asymptomatic HBsAg carriers) [79].
In 5% of anti-HBe-positive children, a pre-core mutant is
selected, with persistent viral replication, abnormal ALT levels
and histologically active hepatitis (HBeAg-negative chronic hepa-
titis). The latter progresses slowly in children, whereas adult
patients are at increased risk of cirrhosis and HCC [53,58,79,80].
A stronger immune response with a faster turnover of infected
cells could account for such an increased severity, and could be
secondary to the reduced secretion of the tolerogenHBeAg [55,81].
In long-term longitudinal studies, it was shown that 7–14% of
inactive carriers lost HBsAg and became anti-HBs-positive. Spon-
taneous seroconversion to anti-HBs is a rare event in childhood
(1%/year and 0.6%/year in horizontally and perinatally infected
children, respectively) [53,58,62,80]. HBsAg clearance and anti-
HBs seroconversion mark the resolution of HBV infection, and
are accompanied by improved liver histology. Long-term progno-
sis after HBsAg seroclearance is excellent if it occurs before the
development of cirrhosis or HCC and in the absence of concomi-888 Journal of Hepatology 201tant infections [82]. Nevertheless, cccDNA persists indeﬁnitely in
hepatocytes, and low-level viral replication or reactivation upon
immunosuppression are still possible.Who and when to treat
Even though several guidelines have been published by major
international societies on the management of adult patients with
CHB, treatment strategies for children are still evolving and are
mostly based on consensus of expert panels (Fig. 1) [83–86].
Decision to start a therapy must take into account the mild evo-
lution of the disease during childhood for most of the patients
and the potentially severe complications in few, not yet well
identiﬁed cases, and it is complicated by the limited number of
drugs labeled for use in children.
The goal of the anti-HBV therapy, in children as in adults, is to
reduce the risk of progressive liver disease, cirrhosis, and HCC. It
can be achieved by suppressing viral replication through durable
HBeAg seroconversion and undetectable serum HBV DNA levels.
Reduction of viremia levels leads to decreased liver inﬂammation2 vol. 57 j 885–896
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and subsequent normalization of ALT levels. The ﬁnal goal is anti-
HBs seroconversion, as it stops disease progression and reduces
the risk of HCC, although it occurs in a minority of treated sub-
jects [87].
Need for treatment should be evaluated at each follow-up
visit, in order to treat as soon as early signs of liver damage are
detected. Children with CHB should undergo physical examina-
tion and measurement of serum ALT, HBeAg/anti-HBe, and
alpha-fetoprotein levels every 6 months. ALT should be moni-
tored every 3 months at diagnosis (for 1 year) and if persistently
elevated, and every 12 months in HBeAg-negative patients with
low viral load (<2000 IU/ml). HBV DNA levels should be assessed
every 12 months, along with a complete blood count, a full liver
panel and a liver ultrasound [83,85,88]. Lifetime follow-up is
warranted even for inactive carriers, because of the risk of cirrho-
sis (7.8% of patients at 25 years), HCC (2.2%) and reactivation of
HBV infection, with seroreversion to HBeAg positivity (1–4% of
patients) or progression to HBeAg-negative hepatitis (15–24%)
[79,89].
Decision to treat should be based on the following parame-
ters: ALT levels, HBeAg positivity, HBV DNA levels, liver histology,
family history of cirrhosis, and/or HCC, co-existing liver diseases,
and patient’s treatment history. Serum ALT level is the most use-
ful marker of liver damage and should be used to identify
patients who could be considered for possible antiviral therapy.
Published evidence suggests that patients with normal or mildly
elevated ALT respond poorly to available treatments [90,91]. Ben-
eﬁt of treating children with normal ALT has not been estab-
lished, and the risk of developing antiviral resistance could turn
it deleterious when considering the future of these patients
[92]. Therefore, children in the immunotolerant phase should
not be treated outside of clinical trials, and should be monitored
and treated when the increase of ALT levels reveals immune acti-
vation. The three largest clinical trials of antiviral drugs in chil-
dren used ALT levels higher than 1.5 times the laboratory ULN
or more than 60 IU/L, whichever was lower, as inclusion criteria
[90,91,93]. Unfortunately, the upper limit of normal (ULN) for
ALT levels has not yet been established for children [94].
Serum ALT level has to be elevated for at least 6 months
(12 months if HBeAg-negative), in order to avoid treating patients
who are undergoing spontaneous HBeAg seroconversion. Persis-
tent ALT elevation mandates assessment of serum HBV DNA lev-
els. High HBV DNA values warrant treatment, whereas low HBV
DNA levels should lead to the exclusion of other causes of liver
disease. The cut-off value for HBV DNA has not been deﬁned,
and arbitrary values are used in clinical trials and guidelines. As
children have a higher HBV replication rate, a value of
20,000 IU/ml has been chosen by different authors [85,95]. How-
ever, lower values have been associated with progressive liver
disease in adults and latest management guidelines identiﬁed
2.000 IU/ml to be a good cut-off [83].
In adult patients older than 40 years of age, treatment can be
started solely upon detection of a high viral load, as it is an inde-
pendent risk factor of cirrhosis and HCC [72,73]. No data exist in
children to support such an approach. Therefore, as response to
currently available treatments for children is partial and limited
to speciﬁc subgroups, histologic assessment of the grade of
inﬂammation and the stage of ﬁbrosis remains recommended
before treating a child. Response to both interferon(IFN)-alfa
and nucleos(t)ide analogues is more likely when at least moder-
ate necroinﬂammation or moderate ﬁbrosis are found at liver his-Journal of Hepatology 201tology [90,96]. Although the beneﬁt of treatment has not been
established for children with mild inﬂammation or ﬁbrosis, a
family history of HCC may warrant treatment even in children
with mild histological changes, as they are at increased risk of
developing HCC [77].
There are other special populations of children at increased
risk of rapid disease progression (cirrhosis, HBV-related glomeru-
lonephritis, co-infection with HDV, HCV, or HIV). These patients
could beneﬁt from treatment even if ALT, HBV DNA levels, and
liver histology do not match the above listed cut-offs. An antiviral
treatment should be always considered in recipients of a liver
graft from an anti-HBc-positive donor and to prevent (or treat)
a recurrent HBV infection in children undergoing liver transplan-
tation [83,97–99]. Furthermore, prophylactic treatment should
be administered to HBsAg-positive patients who have to receive
immunosuppressive or cytotoxic therapy, as it decreases the risk
of mortality and morbidity related to HBV reactivation [100].
Several studies conducted in adults showed a better response
to interferon for viral genotypes A and B, compared to D and C,
respectively [25,101–103]. On the contrary, no signiﬁcant differ-
ence was found when nucleoside analogues were used [104]. No
studies have investigated the role of genotype on treatment
response in pediatric patients, and genotype determination
before treatment is not currently recommended [86].Treatment options
The US Food and Drug Administration (FDA) approved four med-
ications for treatment of children with CHB: IFNa, lamivudine,
adefovir, and entecavir. IFNa can be used in children older than
12 months of age, lamivudine starting at 3 years of age, adefovir
in children aged 12 years and older and entecavir starting from
16 years of age. Each of these treatments, together with others
currently studied or used off-label in reference centers, has
advantages and disadvantages (Table 2), and different response
and resistance rates (Fig. 2).
Interferon-alfa
IFNa-2b has been the ﬁrst drug to be approved and it has been
used to treat CHB in children for about 15 years. Efﬁcacy in chil-
dren is similar to that in adults. In the largest multinational ran-
domized controlled trial of IFNa therapy in children, 26% of
patients achieved virologic response (VR: undetectable HBV
DNA and loss of HBeAg) after 24 weeks of treatment, compared
to 11% of untreated controls, and an additional 7% responded dur-
ing the 24 weeks after treatment cessation. Response rate rose to
35% when only patients with ALT at least twice the ULN were
considered. ALT levels decreased in all responders, and they were
normal in 44% of cases at the end of treatment. Histological activ-
ity index improved in responders and loss of HBsAg occurred in
10% of treated children, as compared to 1.2% in the control group.
Likeliness of a response was associated with low HBV DNA levels
before treatment, younger age and female sex [90]. A better
response in young patients was subsequently conﬁrmed in chil-
dren younger than 5 years of age [105].
IFNa is thought to simply accelerate seroconversion, as many
patients who do not respond to treatment may still seroconvert
to anti-HBe later in life. In three different series of 108, 107,
and 174 children with CHB, IFNa treatment was shown to2 vol. 57 j 885–896 889
Table 2. Available treatments for chronic hepatitis B in pediatric age.
Treatment Licensing Dose Duration Advantages Disadvantages
IFNα ≥12 mo 5-10 M units/m2 sc
3 x/wk
6 mo No resistance
Usable in young children
Short treatment
Heavy side effects
Parenteral administration
Not usable if decompensated 
cirrhosis or transplantation
Lamivudine ≥3 yr 3 mg/kg po 
once daily 
(max 100 mg/d)
≥1 yr Few side effects
Usable in young children
Oral administration
Usable in 3rd trimester of 
pregnancy
High resistance rate (increasing with 
time of treatment)
Adefovir ≥12 yr 10 mg po 
once daily
≥1 yr
(+ 6 mo after HBeAg 
seroconversion)
Partially effective in lamivu-
dine resistant patients
Oral administration
Not approved for children <12 yr
Emergence of resistant mutations
Entecavir ≥16 yr
+ Phase III 
(2-17 yr)
0.5 mg/d once 
daily (1 mg/d for 
lamivudine-
resistant pts)
≥1 yr 
(+ 6 mo after HBeAg 
seroconversion)
Partially effective in lamivu-
dine resistant patients
Oral administration
Resistance rate on the long term
Not approved for children <16 yr
No available preparation for young 
children
PegIFN Phase III 
(2-18 yr)
180 µg/wk 6 mo No resistance
Once weekly administration
Short treatment
Heavy side effects
Parenteral administration
Not usable if decompensated 
cirrhosis or transplantation
Telbivudine Phase I 
(2-18 yr)
600 mg/d 
once daily
≥1 yr Few side effects
Oral administration
Usable in 3rd trimester of 
pregnancy
High resistance rate
Tenofovir Phase III 
(12-17 yr)
300 mg/d 
once daily
≥1 yr High response rate
Few side effects
Oral administration
No resistance identified
Usable in 3rd trimester of 
pregnancy
No available preparation for young 
children
Reduced mineral density in children
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Reviewaccelerate HBeAg seroconversion, but treated and untreated
patients had a similar rate of HBeAg clearance at long-term fol-
low-up (Fig. 3) [53,62,106]. These data were conﬁrmed in a
recent study on Asian children [107]. Furthermore, children of890 Journal of Hepatology 201Asian origin seroconverted slower than those of other ethnic ori-
gin, but they reached the same proportion of seroconversion in
the long-term [62]. In a series of 74 children followed-up for
7 years, treated patients with elevated baseline ALT levels2 vol. 57 j 885–896
80
100
60
40
20
0
P
at
ie
nt
s 
(%
) 60%
65%
94%
86%80%
69%
86%
75%
35%
54%
Studies
Author et al.,
Year,
[Ref.]
Follow-up (yr)
n treated/
untreated
Bortolotti,
2000,
[106]
5
107/59
Marx,
2002,
[62]
13
27/147
Vo Thi Diem,
2005,
[108]
7
37/37
Iorio,
2007,
[53]
12
41/67
Hsu,
2008,
[107]
6
17/21
Fig. 3. HBeAg seroconversion rates in children treated with INF-alfa (light
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JOURNAL OF HEPATOLOGYshowed a higher long-term seroconversion rate, whereas ele-
vated ALT at baseline did not signiﬁcantly inﬂuence the long-
term natural seroconversion rate in untreated children [108].
HBsAg clearance was observed in 4–15% of children treated
with IFN (15–25% of responders), compared to 0–10% of controls
[53,62,90,106–108]. The difference in HBsAg seroconversion rate
between treated and untreated patients was shown to be signif-
icant in the randomized controlled trial, whereas none of long-
term studies was able to ﬁnd such a difference to be statistically
signiﬁcant. Nevertheless, children who responded promptly to
IFN were more likely to lose HBsAg than late or no-responders
[106].
Overall, although pediatric studies failed to show an impact of
treatment over time, large case–control studies and meta-analy-
ses in adults showed that IFNa reduced the risk of cirrhosis (RR
0.65) and HCC (RR 0.59–0.66) in the long-term [109–111].
European consensus recommendations for IFNa treatment
suggest to treat HBeAg-positive children aged 2 years or older,
with abnormal ALT and low-intermediate HBV DNA levels. The
recommended regimen is 5–10 million units per square meter,
three times weekly for 6 months [86,112]. The beneﬁt of priming
with corticosteroids has not been proven [113,114]. IFNa is con-
traindicated in children with decompensated cirrhosis, cytopenia,
autoimmune disorders, cardiac or renal failure, and in trans-
planted patients [112]. As VR may be achieved in the 6 months
following the end of treatment, at least 6–12 months should pass
by before another therapy is started.
Side effects of IFNa treatment included fever and ﬂu-like
symptoms, behavioral disorders, gastrointestinal disorders and
neutropenia [90]. Furthermore, IFNa was shown to temporarily
affect growth [115]. All side effects resolve after treatment is
stopped.
Pegylated interferon-alfa (PegIFN) has not yet been approved
for the treatment of CHB in children. Polyethylene glycol addition
to IFNa enhances its half-life, allowing a once-weekly adminis-
tration. Such a formulation is licensed for the use in children with
chronic hepatitis C. In adults with CHB, PegIFN proved to have
superior efﬁcacy than conventional IFNa, with the same safety
proﬁle [116]. Clinical trials of PegIFN in children with CHB areJournal of Hepatology 201ongoing. Preliminary reports in children with HCV infection
showed that it was well tolerated, while leading to better
response rates than IFNa [117,118].Lamivudine
Lamivudine is a pyrimidine nucleoside analogue approved for
children aged 3 years and older. In the largest pediatric random-
ized, controlled trial, VR was achieved by 23% of patients receiv-
ing lamivudine after 1-year treatment (compared to 13% in the
control group). Response increased to 35% when considering only
children with ALT levels of at least twice the ULN [91]. An open
label extension study was then carried out on the same cohort,
reaching a total of 2 or 3 years of treatment. At the end of the
extension period, response rate was 56% for children receiving
lamivudine in the absence of resistant mutations (being 5% in
patients with a YMDD mutant HBV). Resistance rate increased
over time (24% after 1 year of treatment, 49% at 2 years, and
64% at 3 years) [119]. Likeliness of response was greater in
patients with higher ALT levels and histologic activity index at
baseline. In children, no data is yet available on the long-term
impact of treatment with lamivudine (or any other nucleoside
analogue) on the natural history of the disease.
Lamivudine is well tolerated with no signiﬁcant side effects.
The recommended treatment dose is 3 mg/kg/day (maximum
100 mg/day), administered orally once daily. Such a dose pro-
vides levels of exposure and trough concentrations similar to
the 100 mg dose in adults [120]. Optimal treatment duration is
more difﬁcult to determine. Published data suggest continuing
treatment until VR is achieved, and possibly for 6 months follow-
ing seroconversion [119]. As a longer treatment duration leads to
higher resistance rates, it is recommended to discontinue lamivu-
dine after 6 months if a complete suppression of viral replication
is not achieved or if YMDD mutations emerge. As post-treatment
ALT ﬂares are possible, children should be carefully followed and
an alternative therapy should be started in the rare cases of
severe and protracted ALT elevation [121].
Combination of lamivudine with IFNa (either concurrent or
sequential) proved to bemore effective that the single drugs alone
in adult patients with elevated ALT levels [122,123]. The two
drugs were shown to have a synergistic effect on cells in vitro
[124]. In children, fewer data are available. Three studies investi-
gated combined therapy in 32, 33, and 45 treatment-naïve chil-
dren with elevated ALT levels. Although no difference was found
between different combination strategies, the children reached
30–60% seroconversion to anti-HBe and 9–17% to anti-HBs
[125–127]. An 8-week treatment with lamivudine followed by
10-month combination therapywith lamivudine and IFN has been
tested on 23 immunotolerant children: complete suppression of
viral replication was achieved in 78% of subjects and 22% of chil-
dren seroconverted to anti-HBe. The concurrent administration of
IFNa appeared to be protective against mutations emergence
[128]. No difference was seen on histological response between
monotherapy and combined therapy [129]. As no large clinical
trials have been conducted so far, advantages of combination
therapy over monotherapy in children are still to be conﬁrmed.
Adefovir
Adefovir dipivoxil is a purine analogue approved to treat
children with CHB aged 12 years and older. In a large pediatric2 vol. 57 j 885–896 891
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randomized controlled trial, 23% of patients aged 12–17 years
achieved VR after 48-week treatment with adefovir (compared
to 0% of placebo-treated subjects). The efﬁcacy on HBV DNA sup-
pression and ALT normalization was less evident in younger chil-
dren (15% vs. 3%), with differences between groups not being
statistically signiﬁcant [93]. Adefovir was well tolerated by chil-
dren of all age groups, with no resistance-associated mutation
registered. However, adefovir resistant mutations are reported
in more than 20% of HBeAg-positive adults after a 5-year treat-
ment [130]. A dose-dependent proximal renal tubular toxicity,
with occasional Fanconi-like renal tubular acidosis, is a known
side effect of adefovir, which has been rarely reported in adults,
but never in children. The nephrotoxicity is usually reversible if
the therapy is rapidly stopped [131,132]. The recommended dose
in patients 12–18 years of age is 10 mg orally once daily [133].
Treatment duration has not been established, but experts agree
to continue for at least 6 months after HBeAg seroconversion.
Adefovir should be discontinued if a complete VR is not achieved
after 24 weeks or if a resistant mutation emerges. As with other
nucleos(t)ide analogues, patients should be monitored after dis-
continuation because post-treatment ﬂares are not uncommon.
Entecavir
Entecavir is a carbocyclic analogue of 20-deoxyguanosine that
proved to be more potent than both lamivudine and adefovir in
adult patients [134,135]. Furthermore, entecavir resistance is rare,
even after 5 years of treatment, and entecavir is active (although
less effective) on lamivudine-resistant strains [136–138]. The
safety proﬁle of entecavir is similar to that of lamivudine. Based
on adult studies, entecavir has been approved by the FDA for
treatment of adolescents aged 16 years or older. The recom-
mended dose is 0.5 mg once daily for nucleoside-naïve patients
and 1 mg/day for lamivudine-resistant patients. A phase III clini-
cal trial in children as young as 2 years old is underway [139].
New drugs
Telbivudine is an L-nucleoside analogue with a potent antiviral
activity and a safety proﬁle similar to lamivudine (although
myopathy and peripheral neuropathy were reported in adults)
[140]. Resistance rate is lower than lamivudine but higher than
adefovir. For such a reason, telbivudine is only used in combina-
tion with other antiviral drugs. A phase I clinical trial is ongoing
on children 2–18 years of age [141].
Tenofovir disoproxil fumarate is a nucleos(t)ide analogue
originally licensed for treatment of HIV infection, which is struc-
turally similar to adefovir and of equal antiviral activity. Never-
theless, as it proved to be less nephrotoxic than adefovir, the
approved dose for adults is higher than that of adefovir
(300 mg/day). For such a reason, tenofovir was shown to have a
greater antiviral activity than adefovir in clinical trials (undetect-
able HBV DNA in 76% of patients vs. 13% of adefovir-receiving
subjects after 48 weeks of treatment) [142]. After three years of
treatment, 72% of HBeAg-positive and 87% of HBeAg-negative
patients have HBV DNA levels <400 copies/ml [143]. The safety
proﬁle of tenofovir is similar to that of adefovir, although associ-
ated with decreased bone mineral density in children with HIV
[144]. No genotypic resistance to tenofovir has yet been con-
ﬁrmed [143,145]. Tenofovir is currently used to treat HIV infec-
tion in children, and it proved to be well tolerated in phase I892 Journal of Hepatology 201studies conducted in patients 4–18 years of age [146,147]. As
there is no preparation suitable for young children, a phase III
trial is ongoing on 12–17 year old CHB patients [148].Proposition of a treatment scheme
Outside clinical trials, until new drugs are licensed for pediatric
patients, IFNa is still the drug of choice, unless decompensated
cirrhosis is present. The impossibility of developing a genotypic
resistance against such a drug is a big advantage, even though
adverse effects are more pronounced and a clear beneﬁt on the
long-term period remains to be conﬁrmed. Furthermore, IFNa is
the only treatment licensed for treating children younger than
3 years of age, although patients in this age group requiring treat-
ment, are extremely rare. Currently available nucleos(t)ide ana-
logues are second-line therapies, as the risk of emergence of
resistant mutant strains is high. In adolescents older than
16 years of age, entecavir is the best choice, as resistance is less
likely. Such a risk is higher with both lamivudine and adefovir,
the latter being preferable in children aged 12–15 years. The
use of lamivudine is currently limited to young children unre-
sponsive to IFNa, in special populations (co-infection with HIV,
transplant recipients or patients with HBV-related glomerulone-
phritis) or to prevent reactivation in children receiving immuno-
suppressive therapies. Combination therapy is promising, but
further data are needed in children.
Newer drugs such as PegIFN and tenofovir are extremely
promising and their licensing for children could change manage-
ment of pediatric CHB. As the emergence of resistant mutant
strains is becoming a major public health problem, pediatric
practitioners should refrain from treating children who are not
likely to beneﬁt from a licensed therapy and consider waiting
for safer and more effective drugs made available through clinical
trials or future market approval.Conclusions
A dramatic reduction of pediatric HBV infection prevalence has
been observed in countries where global immunization programs
have been implemented. Nevertheless, an important number of
children are still infected every year. Prevention and manage-
ment of breakthrough infection, along with a better identiﬁcation
of children at higher risk for disease progression and complica-
tions, are the current challenges.
Overall, management of pediatric patients with CHB is satis-
factory, but hampered by a chronic delay in licensing new drugs
as compared to adults. As the approval by regulatory agencies is
based on the completion of appropriate clinical trials, studies on
treatments that, in adults, have already been proved safe and
more effective than available drugs should be conducted without
undue delays. The current (2007) European regulation on medi-
cines for children offers the appropriate regulatory framework
to speed up this process.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.2 vol. 57 j 885–896
JOURNAL OF HEPATOLOGY
References
[1] World Health Organization. Hepatitis B [Internet]. WHO Website. 2008
[cited 25.10.11]; Available from: http://www.who.int/mediacentre/fact-
sheets/fs204/en/index.html.
[2] Lavanchy D, Hepatitis B. Virus epidemiology, disease burden, treatment,
and current and emerging prevention and control measures. J Viral Hepat
2004;11:97–107.
[3] Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A
mathematical model to estimate global hepatitis B disease burden and
vaccination impact. Int J Epidemiol 2005;34:1329–1339.
[4] McMahon BJ. The natural history of chronic hepatitis B virus infection.
Hepatology 2009;49:S45–S55.
[5] Kidd-Ljunggren K, Holmberg A, Bläckberg J, Lindqvist B. High levels of
hepatitis B virus DNA in body ﬂuids from chronic carriers. J Hosp Infect
2006;64:352–357.
[6] Weinbaum CM, Williams I, Mast EE, Wang SA, Finelli L, Wasley A, et al.
Recommendations for identiﬁcation and public health management of
persons with chronic hepatitis B virus infection. MMWR Recomm Rep
2008;57:1–20.
[7] Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A
comprehensive immunization strategy to eliminate transmission of hepa-
titis B virus infection in the United States – recommendations of the
advisory committee on immunization practices (ACIP) Part 1: Immuniza-
tion of infants, children, and adolescents. MMWR Recomm Rep 2005;54:
1–23.
[8] Sokal EM, Van Collie O, Buts JP. Horizontal transmission of hepatitis B from
children to adoptive parents. Arch Dis Child 1995;72:191.
[9] Martin A, Moyes C, Lucas C, Milne A. Hepatitis B infection in households of
HBsAg positive New Zealand children. N Z Med J 1996;109:463–465.
[10] Centers for Disease Control and Prevention CDC. Vaccination coverage
among children in kindergarten–United States, 2009-10 school year.
MMWR Morb Mortal Wkly Rep 2011;60:700-704. .
[11] Bartlett L, Kanellos-Sutton M, van Wylick R. Immunization rates in a
canadian juvenile corrections facility. J Adolesc Health 2008;43:609–611.
[12] Sneller VP, Fishbein DB, Weinbaum CM, Lombard A, Murray P, McLaurin JA,
et al. Vaccinating adolescents in high-risk settings: lessons learned from
experiences with hepatitis b vaccine. Pediatrics 2008;121:S55–S62.
[13] McMahon BJ, Alward WL, Hall DB, Heyward WL, Bender TR, Francis DP,
et al. Acute hepatitis B virus infection: relation of age to the clinical
expression of disease and subsequent development of the carrier state. J
Infect Dis 1985;151:599–603.
[14] Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis
A, Gerin JL, Purcell RH. Natural history of acute hepatitis B surface
antigen-positive hepatitis in Greek adults. Gastroenterology
1987;92:1844–1850.
[15] World Health Organization. Hepatitis B vaccines - WHO position paper.
Weekly epidemiological record 2009;89:405-420.
[16] Chen H-L, Lin L-H, Hu F-C, Lee J-T, Lin W-T, Yang Y-J, et al. Effects of
maternal screening and universal immunization to prevent mother-to-
infant transmission of HBV. Gastroenterology 2011. http://dx.doi.org/
10.1053/j.gastro.2011.12.035.
[17] Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for
newborn infants of hepatitis B surface antigen-positive mothers. Cochrane
Database Syst Rev 2006;Issue 2. Art. No.: CD004790. http://dx.doi.org/
10.1002/14651858.CD004790.pub2.
[18] Chang MH, Lee CY, Chen DS, Hsu HC, Lai MY. Fulminant hepatitis in
children in Taiwan: the important role of hepatitis B virus. J Pediatr
1987;111:34–39.
[19] Chen H-L, Chang C-J, Kong M-S, Huang F-C, Lee H-C, Lin C-C, et al.
Pediatric fulminant hepatic failure in endemic areas of hepatitis B
infection: 15 years after universal hepatitis B vaccination. Hepatology
2004;39:58–63.
[20] Vanclaire J, Cornu C, Sokal EM. Fulminant hepatitis B in an infant born to a
hepatitis Be antibody positive, DNA negative carrier. Arch Dis Child
1991;66:983–985.
[21] Wang Z, Zhang J, Yang H, Li X, Wen S, Guo Y, et al. Quantitative analysis of
HBV DNA level and HBeAg titer in hepatitis B surface antigen positive
mothers and their babies: HBeAg passage through the placenta and the rate
of decay in babies. J Med Virol 2003;71:360–366.
[22] Wen W-H, Chen H-L, Ni Y-H, Hsu H-Y, Kao J-H, Hu F-C, et al. Secular trend
of the viral genotype distribution in children with chronic hepatitis B virus
infection after universal infant immunization. Hepatology 2011;53:
429–436.Journal of Hepatology 201[23] McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O,
et al. Antibody levels and protection after hepatitis B vaccination: results of
a 15-year follow-up. Ann Intern Med 2005;142:333–341.
[24] Hsu H-Y, Chang M-H, Ni Y-H, Chiang C-L, Chen H-L, Wu J-F, et al. No
increase in prevalence of hepatitis B surface antigen mutant in a population
of children and adolescents who were fully covered by universal infant
immunization. J Infect Dis 2010;201:1192–1200.
[25] Xu D-Z, Yan Y-P, Choi BCK, Xu J-Q, Men K, Zhang J-X, et al. Risk factors and
mechanism of transplacental transmission of hepatitis B virus: a case–
control study. J Med Virol 2002;67:20–26.
[26] Yang J, Zeng X-M, Men Y-L, Zhao L-S. Elective caesarean section versus
vaginal delivery for preventing mother to child transmission of hepatitis B
virus – a systematic review. Virol J 2008;5:100.
[27] Bzowej NH, Hepatitis B. Therapy in pregnancy. Curr Hepatitis Rep
2010;9:197–204.
[28] Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM, et al. Lamivudine in late
pregnancy to prevent perinatal transmission of hepatitis B virus infection: a
multicentre, randomized, double-blind, placebo-controlled study. J Viral
Hepat 2009;16:94–103.
[29] Shi Z, Yang Y, Ma L, Li X, Schreiber A. Lamivudine in late pregnancy to
interrupt in utero transmission of hepatitis B virus: a systematic review
and meta-analysis. Obstet Gynecol 2010;116:147–159.
[30] Han G-R, Cao M-K, Zhao W, Jiang H-X, Wang C-M, Bai S-F, et al. A
prospective and open-label study for the efﬁcacy and safety of telbivudine
in pregnancy for the prevention of perinatal transmission of hepatitis B
virus infection. J Hepatol 2011;55:1215–1221.
[31] World Health Organization. Hepatitis B and breastfeeding. World Health
Organization. J Int Assoc Physicians AIDS Care 1998;4:20-21.
[32] Shi Z, Yang Y, Wang H, Ma L, Schreiber A, Li X, et al. Breastfeeding of
newborns by mothers carrying hepatitis B virus: a meta-analysis and
systematic review. Arch Pediatr Adolesc Med 2011;165:837–846.
[33] Petrova M. Breastfeeding and chronic HBV infection: clinical and social
implications. World J Gastroenterol 2010;16:5042–5046.
[34] National Center for Immunization and Respiratory Diseases. General
recommendations on immunization – recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR Recomm Rep
2011;60:1–64.
[35] World Health Organization. Hepatitis B vaccines: WHO position paper—
recommendations. Vaccine 2010;28:589–590.
[36] World Health Organization. Expanded programme on immunization.
Global Advisory Group–Part I. Wkly Epidemiol Rec 1992;67:11–15.
[37] World Health Organization. Global routine vaccination coverage, 2010.
Wkly Epidemiol Rec 2011;86:509–513.
[38] Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy
on hepatitis B virus infections in China over a 20-year period. Int J Infect Dis
2012;16:e82–8.
[39] Chien YC. Nationwide hepatitis B Vaccination program in Taiwan: effec-
tiveness in the 20 years after it was launched. Epidemiol Rev 2006;28:
126–135.
[40] Zanetti AR, van Damme P, Shouval D. The global impact of vaccination
against hepatitis B: a historical overview. Vaccine 2008;26:6266–6273.
[41] Liang X, Bi S, Yang W,Wang L, Cui G, Cui F, et al. Epidemiological serosurvey
of Hepatitis B in China—declining HBV prevalence due to Hepatitis B
vaccination. Vaccine 2009;27:6550–6557.
[42] Ni Y-H, Huang LM, Chang M-H, Yen CJ, Lu CY, You S-L, et al. Two decades of
universal hepatitis B vaccination in Taiwan: impact and implication for
future strategies. Gastroenterology 2007;132:1287–1293.
[43] Chen S-M, Kung C-M, Yang W-J, Wang H-L. Efﬁcacy of the nationwide
hepatitis B infant vaccination program in Taiwan. J Clin Virol 2011;52:
11–16.
[44] Zhang L, Xu A, Yan B, Song L, Li M, Xiao Z, et al. A signiﬁcant reduction in
hepatitis B virus infection among the children of Shandong Province, China:
the effect of 15 years of universal infant hepatitis B vaccination. Int J Infect
Dis 2010;14:e483–e488.
[45] Ioannou GN, Hepatitis B. Virus in the United States: infection, exposure, and
immunity rates in a nationally representative survey. Ann Intern Med
2011;154:319–328.
[46] Stadler LP, Mezoff AG, Staat MA. Hepatitis B virus screening for interna-
tionally adopted children. Pediatrics 2008;122:1223–1228.
[47] Cai W, Poethko-Müller C, Hamouda O, Radun D. Hepatitis B virus infections
among children and adolescents in Germany. Pediatr Infect Dis J
2011;30:19–24.
[48] Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B
antibody is protective? J Infect Dis 1999;179:489–492.2 vol. 57 j 885–896 893
Review
[49] American Academy of Pediatrics. Medical evaluation of internationally
adopted children for infectious diseases. In: Pickering L, Baker C, Long S,
MacMillan J, editors. Red book: 2009 report of the Committee on Infectious
Diseases. Elk Grove Village, IL: American Academy of Pediatrics; 2009. p.
177–184.
[50] Liu HF, Sokal E, Goubau P. Wide variety of genotypes and geographic origins
of hepatitis B virus in Belgian children. J Pediatr Gastroenterol Nutr
2001;32:274–277.
[51] Ni Y-H, Chang M-H, Wang K-J, Hsu H-Y, Chen H-L, Kao J-H, et al. Clinical
relevance of hepatitis B virus genotype in children with chronic infection
and hepatocellular carcinoma. Gastroenterology 2004;127:1733–1738.
[52] Lin C-L, Kao J-H. The clinical implications of hepatitis B virus genotype:
recent advances. J Gastroenterol Hepatol 2011;26:123–130.
[53] Iorio R, Giannattasio A, Cirillo FD, Cirillo F, Alessandro L, Vegnente A. Long-
term outcome in children with chronic hepatitis B: a 24-year observation
period. Clin Infect Dis 2007;45:943–949.
[54] Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function
of the secreted hepatitis B e antigen to induce immunologic tolerance in
utero? Proc Natl Acad Sci U S A 1990;87:6599–6603.
[55] Chen MT, Billaud J-N, Sällberg M, Guidotti LG, Chisari FV, Jones J, et al. A
function of the hepatitis B virus pre-core protein is to regulate the immune
response to the core antigen. Proc Natl Acad Sci U S A 2004;101:
14913–14918.
[56] Milich D. Exploring the biological basis of hepatitis B e antigen in hepatitis
B virus infection. Hepatology 2003;38:1075–1086.
[57] Chen M, Sällberg M, Hughes J, Jones J, Guidotti LG, Chisari FV, et al. Immune
tolerance split between hepatitis B virus pre-core and core proteins. J Virol
2005;79:3016–3027.
[58] Bortolotti F, Guido M, Bartolacci S, Cadrobbi P, Crivellaro C, Noventa F, et al.
Chronic hepatitis B in children after e antigen seroclearance. ﬁnal report of
a 29-year longitudinal study. Hepatology 2006;43:556–562.
[59] Chu C-M, Yeh C-T, Lee C-S, Sheen I-S, Liaw Y-F. Pre-core stop mutant in
HBeAg-positive patients with chronic hepatitis B: clinical characteristics
and correlation with the course of HBeAg-to-anti-HBe seroconversion. J
Clin Microbiol 2002;40:16–21.
[60] Frelin L, Wahlstrom T, Tucker AE, Jones J, Hughes J, Lee BO, et al. A
mechanism to explain the selection of the hepatitis e antigen-negative
mutant during chronic hepatitis B virus infection. J Virol 2009;83:
1379–1392.
[61] Tseng Y-R, Wu J-F, Ni Y-H, Chen H-L, Chen C-C, Wen W-H, et al. Long-term
effect of maternal HBeAg on delayed HBeAg seroconversion in offspring
with chronic hepatitis B infection. Liver Int 2011;31:1373–1380.
[62] Marx G, Martin SR, Chicoine J-F, Alvarez F. Long-term follow-up of chronic
hepatitis B virus infection in children of different ethnic origins. J Infect Dis
2002;186:295–301.
[63] Ni Y-H, Chang M-H, Chen P-J, Tsai K-S, Hsu H-Y, Chen H-L, et al. Viremia
proﬁles in children with chronic hepatitis B virus infection and spontane-
ous e antigen seroconversion. Gastroenterology 2007;132:2340–2345.
[64] Wu J-F, Su Y-R, Chen C-H, Chen H-L, Ni Y-H, Hsu H-Y, et al. Predictive effect
of serial serum alanine aminotransferase levels on spontaneous HBeAg
seroconversion in chronic genotype B and C HBV–infected children. J
Pediatr Gastroenterol Nutr 2012;54:97–100.
[65] Chu CM, Liaw YF. Chronic hepatitis B virus infection acquired in childhood:
special emphasis on prognostic and therapeutic implication of delayed
HBeAg seroconversion. J Viral Hepat 2007;14:147–152.
[66] Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with
clinical outcomes in patients with chronic hepatitis B. Gastroenterology
2000;118:554–559.
[67] Chu C-J, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with
earlier hbeag seroconversion compared with hepatitis B virus genotype C.
Gastroenterology 2002;122:1756–1762.
[68] Livingston SE, Simonetti JP, Bulkow LR, Homan CE, Snowball MM, Cagle HH,
et al. Clearance of hepatitis B e Antigen in patients with chronic hepatitis B
and genotypes A, B, C, D, and F. Gastroenterology 2007;133:1452–1457.
[69] Chang M, Hsu H, Hsu H, Ni Y, Chen J, Chen D. The signiﬁcance of
spontaneous hepatitis B e antigen seroconversion in childhood: with
special emphasis on the clearance of hepatitis B e antigen before 3 years of
age. Hepatology 1995;22:1387–1392.
[70] Wen W-H, Chang M-H, Hsu H-Y, Ni Y-H, Chen H-L. The development of
hepatocellular carcinoma among prospectively followed children with
chronic hepatitis B virus infection. J Pediatr 2004;144:397–399.
[71] Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased
incidence of hepatocellular carcinoma in hepatitis B vaccinees: A 20-year
follow-up study. JNCI J Natl Cancer Inst 2009;101:1348–1355.894 Journal of Hepatology 201[72] Iloeje UH, Yang H-I, Su J, Jen C-L, You S-L, Chen C-J. Predicting cirrhosis risk
based on the level of circulating hepatitis B viral load. Gastroenterology
2006;130:678–686.
[73] Chen C-J, Yang H-I, Su J, Jen C-L, You S-L, Lu S-N, et al. Risk of hepatocellular
carcinoma across a biological gradient of serum hepatitis B virus DNA level.
JAMA 2006;295:65–73.
[74] Sánchez-Tapias JM, Costa J, Mas A, Bruguera M, Rodés J. Inﬂuence of
hepatitis B virus genotype on the long-term outcome of chronic hepatitis B
in western patients. Gastroenterology 2002;123:1848–1856.
[75] Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, et al. Hepatitis B Virus
Genotype and DNA Level and Hepatocellular Carcinoma: A Prospective
Study in Men. JNCI J Natl Cancer Inst 2005;97:265–272.
[76] Livingston SE, Simonetti JP, McMahon BJ, Bulkow LR, Hurlburt KJ, Homan
CE, et al. Hepatitis B virus genotypes in Alaska native people with
hepatocellular carcinoma: preponderance of genotype F. J Infect Dis
2007;195:5–11.
[77] Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of
hepatocellular carcinoma among chronic hepatitis B carriers and their
relatives. J Natl Cancer Inst 2000;92:1159–1164.
[78] Zhang H, Zhai Y, Hu Z, Wu C, Qian J, Jia W, et al. Genome-wide association
study identiﬁes 1p36.22 as a new susceptibility locus for hepatocellular
carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010;42:
767–770.
[79] Hsu Y-S, Chien R-N, Yeh C-T, Sheen I-S, Chiou H-Y, Chu C-M, et al. Long-
term outcome after spontaneous HBeAg seroconversion in patients with
chronic hepatitis B. Hepatology 2002;35:1522–1527.
[80] Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B:
special emphasis on disease progression and prognostic factors. J Hepatol
2008;48:335–352.
[81] Ribeiro RM, Germanidis G, Powers KA, Pellegrin B, Nikolaidis P, Perelson AS,
et al. Hepatitis B virus kinetics under antiviral therapy sheds light on
differences in hepatitis B e antigen positive and negative infections. J Infect
Dis 2010;202:1309–1318.
[82] Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, et al. Long-term
outcome after hepatitis B surface antigen seroclearance in patients with
chronic hepatitis B. Am J Med 2006;119:71e9–71e16.
[83] Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology
2009;50:661–662.
[84] European Association for the Study of the Liver. EASL clinical practice
guidelines: management of chronic hepatitis B. J Hepatol 2009;50:
227–242.
[85] Shah U, Kelly D, Chang M-H, Fujisawa T, Heller S, González-Peralta RP, et al.
Management of chronic hepatitis B in children. J Pediatr Gastroenterol Nutr
2009;48:399–404.
[86] Jonas MM, Block JM, Haber BA, Karpen SJ, London WT, Murray KF, et al.
Treatment of children with chronic hepatitis B virus infection in the United
States: patient selection and therapeutic options. Hepatology 2010;52:
2192–2205.
[87] Simonetti J, Bulkow L, McMahon BJ, Homan C, Snowball M, Negus S, et al.
Clearance of hepatitis B surface antigen and risk of hepatocellular
carcinoma in a cohort chronically infected with hepatitis B virus. Hepatol-
ogy 2010;51:1531–1537.
[88] Haber BA, Block JM, Jonas MM, Karpen SJ, London WT, McMahon BJ, et al.
Recommendations for screening, monitoring, and referral of pediatric
chronic hepatitis B. Pediatrics 2009;124:e1007–e1013.
[89] Fattovich G, Olivari N, Pasino M, D’Onofrio M, Martone E, Donato F. Long-
term outcome of chronic hepatitis B in Caucasian patients: mortality after
25 years. Gut 2008;57:84–90.
[90] Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, et al.
Interferon alfa therapy for chronic hepatitis B in children: a multinational
randomized controlled trial. Gastroenterology 1998;114:988–995.
[91] Jonas MM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al.
Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J
Med 2002;346:1706–1713.
[92] Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide
analogues. Gastroenterology 2009;137:1593–1608.
[93] Jonas MM, Kelly D, Pollack H, Mizerski J, Sorbel J, Frederick D, et al. Safety,
efﬁcacy, and pharmacokinetics of adefovir dipivoxil in children and
adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology
2008;47:1863–1871.
[94] Schwimmer JB, Dunn W, Norman GJ, Pardee PE, Middleton MS, Kerkar N,
et al. SAFETY study: alanine aminotransferase cut-off values are set too
high for reliable detection of pediatric chronic liver disease. Gastroenter-
ology 2010;138:1357–1364.2 vol. 57 j 885–896
JOURNAL OF HEPATOLOGY
[95] Hsu EK, Murray KF. Hepatitis B and C in children. Nature Clin Prac
Gastroenterol Hepatol 2008;5:311–320.
[96] Hom X, Little NR, Gardner SD, Jonas MM. Predictors of virologic response to
lamivudine treatment in children with chronic hepatitis B infection. Pediatr
Infect Dis J 2004;23:441–445.
[97] Shapira R, Mor E, Bar-Nathan N, Sokal EM, Tur-Kaspa R, Dinari G, et al.
Efﬁcacy of lamivudine for the treatment of hepatitis B virus
infection after liver transplantation in children. Transplantation
2001;72:333–336.
[98] Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-
hepatitis B core positive donors: a systematic review. J Hepatol
2010;52:272–279.
[99] Perrillo R, Hepatitis B. Virus prevention strategies for antibody to hepatitis
B core antigen-positive liver donation: a survey of North American,
European, and Asian-Paciﬁc transplant programs. Liver Transpl 2009;15:
223–232.
[100] Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Lamivudine
prevents reactivation of hepatitis B and reduces mortality in immunosup-
pressed patients: systematic review and meta-analysis. J Viral Hepat
2008;15:89–102.
[101] Wai CT, Chu C-J, Hussain M, Lok ASF. HBV genotype B is associated with
better response to interferon therapy in HBeAg(+) chronic hepatitis than
genotype C. Hepatology 2002;36:1425–1430.
[102] Erhardt A. Response to interferon alfa is hepatitis B virus genotype
dependent: genotype A is more sensitive to interferon than genotype D.
Gut 2005;54:1009–1013.
[103] Flink HJ, van Zonneveld M, Hansen BE, de Man RA, Schalm SW, Janssen HLA,
et al. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic
hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroen-
terol 2006;101:297–303.
[104] Raimondi S, Maisonneuve P, Bruno S, Mondelli MU. Is response to antiviral
treatment inﬂuenced by hepatitis B virus genotype? J Hepatol
2010;52:441–449.
[105] Kobak GE, MacKenzie T, Sokol RJ, Narkewicz MR. Interferon treatment for
chronic hepatitis B: enhanced response in children 5 years old or younger. J
Pediatr 2004;145:340–345.
[106] Bortolotti F, Jara P, Barbera C, Gregorio GV, Vegnente A, Zancan L, et al.
Long-term effect of alpha interferon in children with chronic hepatitis B.
Gut 2000;46:715–718.
[107] Hsu H-Y, Tsai H-Y, Wu T-C, Chiang C-L, Ni Y-H, Chen P-J, et al. Interferon-a
treatment in children and young adults with chronic hepatitis B: a long-
term follow-up study in Taiwan. Liver Int 2008;28:1288–1297.
[108] Vo Thi Diem H, Bourgois A, Bontems P, Goyens P, Buts J-P, Nackers F, et al.
Chronic hepatitis B infection: long-term comparison of children receiving
interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr
2005;40:141–145.
[109] Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, et al. Interferon
therapy in HBeAg positive chronic hepatitis reduces progression to
cirrhosis and hepatocellular carcinoma. J Hepatol 2007;46:45–52.
[110] Yang YF, Zhao W, Zhong YD, Xia HM, Shen L, Zhang N. Interferon therapy in
chronic hepatitis B reduces progression to cirrhosis and hepatocellular
carcinoma: a meta-analysis. J Viral Hepat 2009;16:265–271.
[111] Sung JJY, Tsoi KKF, Wong VWS, Li KCT, Chan HLY. Meta-analysis: treatment
of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment
Pharmacol Ther 2008;28:1067–1077.
[112] Jara P, Bortolotti F. Interferon-alpha treatment of chronic hepatitis B in
childhood: a consensus advice based on experience in European children. J
Pediatr Gastroenterol Nutr 1999;29:163–170.
[113] Boxall EH, Sira J, Ballard AL, Davies P, Kelly DA. Long-term follow-up of
hepatitis B carrier children treated with interferon and prednisolone. J Med
Virol 2006;78:888–895.
[114] Gregorio GV, Jara P, Hierro L, Diaz C, La Vega de A, et al. Lymphoblastoid
interferon alfa with or without steroid pretreatment in children with
chronic hepatitis B: a multicenter controlled trial. Hepatology 1996;23:
700–707.
[115] Comanor L, Minor J, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, et al.
Impact of chronic hepatitis B and interferon-alpha therapy on growth of
children. J Viral Hepat 2001;8:139–147.
[116] Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T,
et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of
hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:
298–305.
[117] Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, et al.
Peginterferon alfa-2b plus ribavirin treatment in children and adolescents
with chronic hepatitis C. Hepatology 2005;41:1013–1018.Journal of Hepatology 201[118] Sokal EM, Bourgois A, Stephenne X, Silveira T, Porta G, Gardovska D, et al.
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in
children and adolescents. J Hepatol 2010;52:827–831.
[119] Sokal EM, Kelly DA, Mizerski J, Badia IB, Areias JA, Schwarz KB, et al. Long-
term lamivudine therapy for children with HBeAg-positive chronic hepa-
titis B. Hepatology 2006;43:225–232.
[120] Sokal EM, Roberts EA, Mieli-Vergani G, McPhillips P, Johnson M, Barber J,
et al. A dose ranging study of the pharmacokinetics, safety, and preliminary
efﬁcacy of lamivudine in children and adolescents with chronic hepatitis B.
Antimicrob Agents Chemother 2000;44:590–597.
[121] Jonas MM, Little NR, Gardner SD. International Pediatric Lamivudine
Investigator Group. Long-term lamivudine treatment of children with
chronic hepatitis B: durability of therapeutic responses and safety. J Viral
Hepat 2008;15:20–27.
[122] Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, et al.
Lamivudine and alpha interferon combination treatment of patients with
chronic hepatitis B infection: a randomised trial. Gut 2000;46:562–568.
[123] Sarin SK, Kumar M, Kumar R, Kazim SN, Guptan RC, Sakhuja P, et al. Higher
efﬁcacy of sequential therapy with interferon-alpha and lamivudine
combination compared to lamivudine monotherapy in HBeAg positive
chronic hepatitis B patients. Am J Gastroenterol 2005;100:2463–2471.
[124] Korba B, Cote P, Hornbuckle W, Schinazi R, Gangemi J, Tennant B, et al.
Enhanced antiviral beneﬁt of combination therapy with lamivudine and
alpha interferon against WHV replication in chronic carrier woodchucks.
Antivir Ther 2000;5:95–104.
[125] Dikici B, Bosnak M, Bosnak V, Dagli A, Ece A, Yagci RV, et al. Combination
therapy for children with chronic hepatitis B virus infection. J Gastroenterol
Hepatol 2002;17:1087–1091.
[126] Yilmaz A, Akcam M, Gelen T, Artan R. Lamivudine and high-dose interferon
alpha 2a combination treatment in naïve HBeAg-positive immunoactive
chronic hepatitis B in children: an East Mediterranean center’s experience.
Eur J Pediatr 2006;166:195–199.
[127] Akman SA, Okcu SC, Halicioglu O, Sutcuoglu S, Anil M, Kizilgunesler A, et al.
Therapeutic efﬁcacy of sequential and simultaneous treatments with
interferon-alpha and lamivudine in children with chronic hepatitis B.
Pediatr Int 2007;49:848–852.
[128] D’Antiga L, Aw M, Atkins M, Moorat A, Vergani D, Mieli-Vergani G.
Combined lamivudine/interferon-alpha treatment in ‘‘immunotolerant’’
children perinatally infected with hepatitis B: a pilot study. J Pediatr
2006;148:228–233.
[129] Kuloglu Z, Krsaçloglu CT, Kansu A, Erden E, Girgin N. Liver histology of
children with chronic hepatitis treated with interferon-alpha alone or in
combination with lamivudine. J Pediatr Gastroenterol Nutr
2007;45:564–568.
[130] Marcellin P, Chang T-T, Lim SGL, Sievert W, Tong M, Arterburn S, et al. Long-
term efﬁcacy and safety of adefovir dipivoxil for the treatment of hepatitis
B e antigen-positive chronic hepatitis B. Hepatology 2008;48:750–758.
[131] Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B.
Hepatology 2009;49:S185–S195.
[132] Viganò M, Lampertico P, Colombo M. Drug safety evaluation of adefovir in
HBV infection. Expert Opin Drug Safety 2011;10:809–818.
[133] Sokal EM, Kelly D, Wirth S, Mizerski J, Dhawan A, Frederick D. The
pharmacokinetics and safety of adefovir dipivoxil in children and adoles-
cents with chronic hepatitis B virus infection. J Clin Pharmacol 2008;48:
512–517.
[134] Chang T-T, Gish RG, de Man R, Gadano A, Sollano J, Chao Y-C, et al. A
comparison of entecavir and lamivudine for HBeAg-positive chronic
hepatitis B. N Engl J Med 2006;354:1001–1010.
[135] Leung N, Peng C-Y, Hann H-W, Sollano J, Lao-Tan J, Hsu C-W, et al. Early
hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients
with chronic hepatitis B: a randomized international study of entecavir
versus adefovir. Hepatology 2009;49:72–79.
[136] Colonno RJ, Rose R, Baldick CJ, Levine S, Pokornowski K, Yu CF, et al.
Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Hepatology 2006;44:1656–1665.
[137] Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al.
Long-term monitoring shows hepatitis B virus resistance to entecavir in
nucleoside-naïve patients is rare through 5 years of therapy. Hepatology
2009;49:1503–1514.
[138] Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw Y-F, Rustgi VK, et al.
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved
virologic, biochemical, and serology outcomes through 96 weeks. Hepa-
tology 2008;48:99–108.
[139] Bristol-Myers Squibb. A Phase III Study of the Safety and Efﬁcacy of
Entecavir in Pediatric Patients With Chronic HBV-Infection. In: ClinicalTri-2 vol. 57 j 885–896 895
Review
als.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000
– [cited 18.09.11]. Available from: http://clinicaltrials.gov/show/
NCT01079806 NLM Identiﬁer: NCT01079806.
[140] Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-year GLOBE
trial results: telbivudine is superior to lamivudine in patients with chronic
hepatitis B. Gastroenterology 2009;136:486–495.
[141] Novartis Pharmaceuticals. Pharmacokinetics and Safety of Single-Dose
Telbivudine in Children and Adolescents With Chronic Hepatitis B. In:
ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine
(US). 2000 – [cited 18.09.11]. Available from: http://clinicaltrials.gov/show/
NCT00907894 NLM Identiﬁer: NCT00907894.
[142] Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al.
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepa-
titis B. N Engl J Med 2008;359:2442–2455.
[143] Heathcote EJ, Marcellin P, Buti M, Gane E, de Man RA, Krastev Z, et al.
Three-year efﬁcacy and safety of tenofovir disoproxil fumarate treatment
for chronic hepatitis B. Gastroenterology 2011;140:132–143.
[144] Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone
mineral density with off-label use of tenofovir in children and adolescents
infected with human immunodeﬁciency virus. J Pediatr 2008;152:
582–584.
[145] Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J, et al.
No resistance to tenofovir disoproxil fumarate detected after up to 144
weeks of therapy in patients monoinfected with chronic hepatitis B virus.
Hepatology 2011;53:763–773.
[146] Hazra R, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, et al.
Single-dose and steady-state pharmacokinetics of tenofovir disoproxil
fumarate in human immunodeﬁciency virus-infected children. Antimicrob
Agents Chemother 2004;48:124–129.
[147] Bouazza N, Urien S, Hirt D, Frange P, Rey E, Benaboud S, et al. Population
pharmacokinetics of tenofovir in HIV-1 infected pediatric patients. J Acquir
Immune Deﬁc Syndr 2011;58:283–288.
[148] Gilead Sciences. Evaluation of Tenofovir Disoproxil Fumarate in Adoles-
cents With Chronic Hepatitis B Infection. In: ClinicalTrials.gov [Internet].
Bethesda (MD): National Library of Medicine (US). 2000 – [cited 18.09.11].
Available from: http://clinicaltrials.gov/show/NCT00734162 NLM Identi-
ﬁer: NCT00734162.
[149] Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global
epidemiology of hepatitis B virus. J Clin Gastroenterol 2004;38:S158–68.
[150] Tessema B, Yismaw G, Kassu A, Amsalu A, Mulu A, Emmrich F, et al.
Seroprevalence of HIV, HBV, HCV and syphilis infections among blood
donors at Gondar University Teaching Hospital, Northwest Ethiopia:
declining trends over a period of ﬁve years. BMC Infect Dis 2010;10:111.
[151] Andernach IE, Nolte C, Pape JW, Muller CP. Slave Trade and Hepatitis B
Virus Genotypes and Subgenotypes in Haiti and Africa. Emerg Infect Dis
2009;15:1222–1228.
[152] Mitchell T, Armstrong GL, Hu DJ, Wasley A, Painter JA. The increasing
burden of imported chronic hepatitis B — United States, 1974–2008. PLoS
ONE 2011;6:e27717.
[153] Juon H-S, Choi K, Park E-C, Kwak M-S, Lee S. Hepatitis B vaccinations among
Koreans: results from 2005 Korea National Cancer Screening Survey. BMC
Infect Dis 2009;9:185.
[154] Chang M-H. Impact of hepatitis B vaccination on hepatitis B disease and
nucleic acid testing in high-prevalence populations. J Clin Virol
2006;36:S45–S50.
[155] Alvarado-Mora MV, Gutierrez Fernandez MF, Gomes-Gouvêa MS, de
Azevedo Neto RS, Carrilho FJ, Pinho JRR. Hepatitis B (HBV), hepatitis C896 Journal of Hepatology 201(HCV) and hepatitis delta (HDV) viruses in the Colombian population—how
is the epidemiological situation? PLoS ONE 2011;6:e18888.
[156] Nguyen VTT, Law MG, Dore GJ. An enormous hepatitis B virus-related liver
disease burden projected in Vietnam by 2025. Liver Int 2008;28:525–531.
[157] Magdzik WW, Hepatitis B. Epidemiology in Poland, Central and Eastern
Europe and the newly independent states. Vaccine 2000;18:S13–6.
[158] Pereira LMMB, Martelli CMT, Merchán-Hamann E, Montarroyos UR, Braga
MC, de Lima MLC, et al. Population-based multicentric survey of hepatitis B
infection and risk factor differences among three regions in Brazil. Am J
Trop Med Hyg 2009;81:240–247.
[159] Livramento AD, de Cordova CMM, Spada C, Treitinger A. Seroprevalence of
hepatitis B and C infection markers among children and adolescents in the
southern Brazilian region. Rev Inst Med Trop Sau Paulo 2011;53:13–17.
[160] Datta S. An overview of molecular epidemiology of hepatitis B virus (HBV)
in India. Virol J 2008;5:156.
[161] Ugwuja E, Ugwu N. Seroprevalence of hepatitis B surface antigen and liver
function tests among adolescents in Abakaliki, South Eastern Nigeria.
Internet J Trop Med 2010;6, Number 2.
[162] Eke AC, Eke UA, Okafor CI, Ezebialu IU, Ogbuagu C. Prevalence, correlates
and pattern of hepatitis B surface antigen in a low resource setting. Virol J
2011;8:12.
[163] Alikor E, Erhabor O. Seroprevalence of hepatitis B surface antigenaemia in
children in a tertiary health institution in the Niger Delta of Nigeria. Niger J
Med 2007;16:326–329.
[164] Nurgalieva ZZ, Hollinger FB, Graham DY, Zhangabylova S, Zhangabylov A.
Epidemiology and transmission of hepatitis B and C viruses in Kazakhstan.
World J Gastroenterol 2007;13:1204–1207.
[165] Allain JP. The risk of hepatitis B virus infection by transfusion in Kumasi.
Ghana. Blood 2003;101:2419–2425.
[166] Olinger CM, Lazouskaya NV, Eremin VF, Muller CP. Multiple genotypes and
subtypes of hepatitis B and C viruses in Belarus: similarities with Russia
and western European inﬂuences. Clin Microbiol Infect 2008;14:575–581.
[167] Thüring E, Joller-Jemelka H, Sereth H, Reth C, Grob P. Prevalence of markers
of hepatitis viruses A, B, C and of HIV in healthy individuals and patients of
a Cambodian province. Southeast Asian J Trop Med Public Health
1993;24:239–249.
[168] Bonanni P, Pesavento G, Bechini A, Tiscione E, Mannelli F, Benucci C, et al.
Impact of universal vaccination programmes on the epidemiology of
hepatitis B: 10 years of experience in Italy. Vaccine 2003;21:685–691.
[169] Meffre C, Le Strat Y, Delarocque-Astagneau E, Dubois F, Antona D, Lemasson
J-M, et al. Prevalence of hepatitis B and hepatitis C virus infections in
France in 2004: Social factors are important predictors after adjusting for
known risk factors. J Med Virol 2010;82:546–555.
[170] Zhang J, Zou S, Giulivi A. Epidemiology of hepatitis B in Canada. Can J Infect
Dis 2001;12:345–350.
[171] Wong D, Cheung A, O’Rourke K, Naylor C, Detsky A, Heathcote J. Effect of
alpha-interferon treatment in patients with hepatitis B e antigen-positive
chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312–323.
[172] Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al.
Lamivudine as initial treatment for chronic hepatitis B in the United States.
N Engl J Med 1999;341:1256–1263.
[173] Marcellin P, Chang T-T, Lim S-G, Tong MJ, Sievert W, Shiffman ML, et al.
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive
chronic hepatitis B. N Engl J Med 2003;348:808–816.
[174] Lau GKK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al.
Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive
chronic hepatitis B. N Engl J Med 2005;352:2682–2695.2 vol. 57 j 885–896
